FDA calls for investigation of Biogen Alzheimer’s drug approval

Following weeks of pushback by physicians, watchdog groups and members of Congress, the head of the U.S. Food and Drug Administration has formally called for an investigation into the approval of Aduhelm, the Alzheimer’s disease drug made by Biogen Inc. (Nasdaq: BIIB).